Lilly, MiNA Ink Broad RNA Deal Worth $1.25B

  • Eli Lilly and Company LLY has struck a deal with MiNA Therapeutics to develop small activating RNA (saRNA) candidates against up to five targets across its key therapeutic focus areas.
  • Lilly is paying $25 million upfront and committing to milestones of up to $245 million per target to work with MiNA.
  • MiNA will also receive tiered royalties from the low-single to low-double digits on product sales resulting from the collaboration.
  • Lilly is already active in the broader RNA space, having entered into deals with Avidity BiosciencesDicerna Pharmaceuticals, and Evox Therapeutics.
  • “Small activating RNAs are a promising new technology, which will expand the breadth of Lilly’s RNA therapeutics platform and the targets we can pursue. We are excited about the potential of combining MiNA’s leading saRNA platform and our expertise in new modalities to accelerate the development of RNA-based medicines in areas of high unmet medical need,” Andrew Adams, VP for new therapeutic modalities at Lilly, said in a statement.
  • Price Action: LLY shares are down 0.40% at $193.99 on the last check Tuesday.

Posted In: BriefsBiotechNewsHealth CareContractsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.